CENTOCOR REPORTS LOSSCentocor Inc. (NASDAQ:CNTO) of Malvern, Pa., said a pre-taxcharge to earnings for acquired research and developmentaccounted for $115 million of fiscal 1990's $132 millionloss.The company will purchase the limited partners' interest inCentocor Cardiovascular Imaging Partners, L.P. and CentocorPartners II, L.P. Chairman and Chief Executive Officer HubertJ.P. Schoemaker said Centocor's cash position is unaffected bythe charge to earnings and stands at more than $190 million.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $17,038 22,339 +24Net income (loss) (132,334) 26 n/aNet income per share (loss) (9.49) 0 n/aOutstanding shares 13,952 11,691 +19

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $64,634 71,960 -10Net income (loss) (132,180) 115 n/aNet income per share (loss) (10.20) 0.01 n/aOutstanding shares 12,965 11,610 +12

APPLIED BIOSCIENCE BOOSTS REVENUE, EARNINGS

Applied Bioscience International (NASDAQ:APBI) of EastMilstone, N.J.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $27,771 22,421 +24Net income (loss) 2,473 1,867 +33Net income per share (loss) 0.23 0.18 +28Outstanding shares 10,614 10,326 +3

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $99,650 78,210 +27Net income (loss) 8,149 6,101 +34Net income per share (loss) 0.77 0.60 n/aOutstanding shares 10,530 10,202 +3

(c) 1997 American Health Consultants. All rights reserved.